Evidence map›Paper›PMID 38856019›Full record

ArticleESC heart failure2024

Heart failure patients' perspectives on treatment outcomes and unmet medical needs: A qualitative preference study.

Alice Vanneste, Liese Barbier, Ramses Missotten, Thomas Desmet, Walter Droogné, Sissel Michelsen, Peter Sinnaeve, Tom Adriaenssens, Isabelle Huys, Rosanne Janssens

Abstract read
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alice VannesteDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Liese BarbierDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Ramses MissottenDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Thomas DesmetDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Walter DroognéDepartment of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
Sissel MichelsenBoehringer Ingelheim Scomm, Brussels, Belgium.
Peter SinnaeveDepartment of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
Tom AdriaenssensDepartment of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
Isabelle HuysDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Rosanne JanssensDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDecision-makers still predominantly focus on the perspective of non-patient stakeholders, which may deviate from the unique perspective of heart failure (HF) patients. To enhance patient-centred decision-making, there is a need for more patient-based evidence derived directly from the patients themselves. Hence, this study aimed to understand (i) HF patients' unmet medical needs and preferred treatment outcomes; (ii) patients' risk tolerance; and (iii) their information needs, uncertainties and satisfaction towards HF treatment.

methodsThis qualitative patient preference study consisted of a literature review with a systematic search strategy and semi-structured interviews with HF patients, analysed using the framework method. During the interviews, patients were asked to rank a predefined list of disease and treatment-related characteristics informed by the literature review and were able to spontaneously raise additional characteristics.

resultsThe study included 14 Belgian HF patients (age range: 58-79, mean age: 72). (i) Regarding their unmet medical needs, HF patients reported that the most important unmet medical needs were shortness of breath and fatigue, as they negatively impact their quality of life (QoL) and independence. In the ranking exercise, patients prioritized improvements in QoL over improvements in life expectancy, whereby the following characteristics received the highest cumulative score: (1) independence, (2) shortness of breath, (3) impaired renal function, (4) survival, (5) fatigue, (6) risk of hospitalization and (7) communication with and between physicians. Patients most often spontaneously raise characteristics related to the general care process. Mechanism of action, route of administration, dose frequency and weight fluctuations scored among the least important characteristics. (ii) Regarding patients' risk tolerance towards HF treatment, some of the patients expressed zero tolerance for side effects, as they had not yet experienced any discomfort caused by the treatment or disease. (iii) Regarding their information needs, patients voiced their desire to receive practical and comprehensible advice orally from their physician because they highly value individualized treatment decision-making. Patients also expressed uncertainties regarding whether the experienced effects were due to their treatment, disease, ageing or other comorbidities.

conclusionsThis study shows that, besides increasing life expectancy, HF patients prioritize improvements in symptoms and side effects reducing their QoL and independence, such as shortness of breath and fatigue. The patient-relevant characteristics identified in this study, from the perspective of HF patients themselves, may be useful to inform clinical trial endpoint selection and guide downstream drug development, evaluation and clinical decision-making towards addressing the unmet medical needs and treatment outcomes of importance to HF patients.

Indexed as

Heart FailurePatient PreferenceQuality of LifeAgedFemaleHealth Services Needs and DemandHumansMaleMiddle AgedQualitative ResearchTreatment Outcomeheart failurepatient‐based evidencepatient‐centred decision‐makingpatient preference studyqualitative researchquality of life

Identifiers

PMID38856019
PMCPMC11424311

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.